PDCD1 and non-small cell lung carcinoma: The addition of the PD-1 inhibitor, pembrolizumab, to the combination of a platinum agent and pemetrexed has recently become a standard first-line treatment for patients with previously untreated metastatic nonsquamous NSCLC without driver oncogenes.3